KIF20B
Kinesin-like protein KIF20B
Also known as: CT90, KI20B_HUMAN, KRMP1, MPHOSPH1, MPP1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96Q89
- Gene
- KIF20B
- Ensembl
- ENSG00000138182
- Chromosome
- 10
- Canonical length
- 1820 aa
- Protein class
- Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytokinetic bridge,Midbody,Centrosome,Basal body,Cytosol,Perinuclear theca
OverviewNCBI Gene
Enables several functions, including ATP hydrolysis activity; WW domain binding activity; and plus-end-directed microtubule motor activity. Involved in positive regulation of cell population proliferation and positive regulation of cytokinesis. Located in several cellular components, including microtubule cytoskeleton; midbody; and nuclear lumen. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
1820 residues, UniProt reviewed canonical sequence.
>Q96Q89|KIF20B
1 MESNFNQEGV PRPSYVFSAD PIARPSEINF DGIKLDLSHE FSLVAPNTEA NSFESKDYLQ
61 VCLRIRPFTQ SEKELESEGC VHILDSQTVV LKEPQCILGR LSEKSSGQMA QKFSFSKVFG
121 PATTQKEFFQ GCIMQPVKDL LKGQSRLIFT YGLTNSGKTY TFQGTEENIG ILPRTLNVLF
181 DSLQERLYTK MNLKPHRSRE YLRLSSEQEK EEIASKSALL RQIKEVTVHN DSDDTLYGSL
241 TNSLNISEFE ESIKDYEQAN LNMANSIKFS VWVSFFEIYN EYIYDLFVPV SSKFQKRKML
301 RLSQDVKGYS FIKDLQWIQV SDSKEAYRLL KLGIKHQSVA FTKLNNASSR SHSIFTVKIL
361 QIEDSEMSRV IRVSELSLCD LAGSERTMKT QNEGERLRET GNINTSLLTL GKCINVLKNS
421 EKSKFQQHVP FRESKLTHYF QSFFNGKGKI CMIVNISQCY LAYDETLNVL KFSAIAQKVC
481 VPDTLNSSQE KLFGPVKSSQ DVSLDSNSNS KILNVKRATI SWENSLEDLM EDEDLVEELE
541 NAEETQNVET KLLDEDLDKT LEENKAFISH EEKRKLLDLI EDLKKKLINE KKEKLTLEFK
601 IREEVTQEFT QYWAQREADF KETLLQEREI LEENAERRLA IFKDLVGKCD TREEAAKDIC
661 ATKVETEETH NYVGFEDIID SLQDNVADIK KQAEIAHLYI ASLPDPQEAT ACLELKFNQI
721 KAELAKTKGE LIKTKEELKK RENESDSLIQ ELETSNKKII TQNQRIKELI NIIDQKEDTI
781 NEFQNLKSHM ENTFKCNDKA DTSSLIINNK LICNETVEVP KDSKSKICSE RKRVNENELQ
841 QDEPPAKKGS IHVSSAITED QKKSEEVRPN IAEIEDIRVL QENNEGLRAF LLTIENELKN
901 EKEEKAELNK QIVHFQQELS LSEKKNLTLS KEVQQIQSNY DIAIAELHVQ KSKNQEQEEK
961 IMKLSNEIET ATRSITNNVS QIKLMHTKID ELRTLDSVSQ ISNIDLLNLR DLSNGSEEDN
1021 LPNTQLDLLG NDYLVSKQVK EYRIQEPNRE NSFHSSIEAI WEECKEIVKA SSKKSHQIEE
1081 LEQQIEKLQA EVKGYKDENN RLKEKEHKNQ DDLLKEKETL IQQLKEELQE KNVTLDVQIQ
1141 HVVEGKRALS ELTQGVTCYK AKIKELETIL ETQKVECSHS AKLEQDILEK ESIILKLERN
1201 LKEFQEHLQD SVKNTKDLNV KELKLKEEIT QLTNNLQDMK HLLQLKEEEE ETNRQETEKL
1261 KEELSASSAR TQNLKADLQR KEEDYADLKE KLTDAKKQIK QVQKEVSVMR DEDKLLRIKI
1321 NELEKKKNQC SQELDMKQRT IQQLKEQLNN QKVEEAIQQY ERACKDLNVK EKIIEDMRMT
1381 LEEQEQTQVE QDQVLEAKLE EVERLATELE KWKEKCNDLE TKNNQRSNKE HENNTDVLGK
1441 LTNLQDELQE SEQKYNADRK KWLEEKMMLI TQAKEAENIR NKEMKKYAED RERFFKQQNE
1501 MEILTAQLTE KDSDLQKWRE ERDQLVAALE IQLKALISSN VQKDNEIEQL KRIISETSKI
1561 ETQIMDIKPK RISSADPDKL QTEPLSTSFE ISRNKIEDGS VVLDSCEVST ENDQSTRFPK
1621 PELEIQFTPL QPNKMAVKHP GCTTPVTVKI PKARKRKSNE MEEDLVKCEN KKNATPRTNL
1681 KFPISDDRNS SVKKEQKVAI RPSSKKTYSL RSQASIIGVN LATKKKEGTL QKFGDFLQHS
1741 PSILQSKAKK IIETMSSSKL SNVEASKENV SQPKRAKRKL YTSEISSPID ISGQVILMDQ
1801 KMKESDHQII KRRLRTKTAKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KIF20B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.49
- Highest tissue expression
- 9.6 nTPM
Expression across tissuesHPA
Tissue
- bone marrow: 9.6 nTPM
- thymus: 9.1 nTPM
- lymph node: 7.4 nTPM
- tonsil: 7 nTPM
- testis: 6.5 nTPM
- appendix: 4.2 nTPM
Single-cell type
- monocyte progenitors: 234 nCPM
- erythrocyte progenitors: 233 nCPM
- early primary spermatocytes: 187 nCPM
- differentiating spermatogonia: 137 nCPM
- megakaryocyte progenitors: 135 nCPM
- late primary spermatocytes: 90 nCPM
Immune cell
- naive B-cell: 16 nTPM
- basophil: 13 nTPM
- memory B-cell: 13 nTPM
- T-reg: 9.5 nTPM
- naive CD4 T-cell: 8.6 nTPM
- naive CD8 T-cell: 8 nTPM
Brain region
- cerebellum: 6.5 nTPM
- basal ganglia: 3.4 nTPM
- thalamus: 2.8 nTPM
- pons: 2.6 nTPM
- white matter: 2.6 nTPM
- medulla oblongata: 2.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about KIF20B.
Disease | ImmuneIEDB
Conditions an epitope on KIF20B was assayed in.
- bladder urothelial carcinoma T cell
- esophageal cancer T cell
- cholangiocarcinoma T cell
- colorectal cancer T cell
- lung cancer T cell
- urinary bladder cancer T cell
ReferencesPubMed · IEDB
Publications for KIF20B from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
3 publications
- Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus.
2024 · Lupus Sci Med · RCR 0.8 · 4 citations - A Monoclonal Antibody to M-Phase Phosphoprotein 1/Kinesin-Like Protein KIF20B.
2019 · Monoclon Antib Immunodiagn Immunother · RCR 0.5 · 10 citations - Anti-KIF20B autoantibodies in systemic autoimmune rheumatic diseases: Their high prevalence in systemic lupus erythematosus.
2023 · J Dermatol · RCR 0.1 · 1 citations
Reference: T cellIEDB
6 publications
- Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for bladder cancer.
2012 · Jpn J Clin Oncol · RCR 1.5 · 63 citations - Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
2016 · Clin Immunol · RCR 1.5 · 51 citations - A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
2017 · Ann Oncol · RCR 1.3 · 47 citations - Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
2020 · Cancer Immunol Immunother · RCR 1.1 · 26 citations - Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer.
2018 · Cancer Immunol Immunother · RCR 0.5 · 16 citations
Show 1 more
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.69
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.6
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell division
- microtubule-based movement
- neural tube closure
- neuron projection morphogenesis
- positive regulation of cell population proliferation
- positive regulation of cytokinesis
- positive regulation of intracellular protein transport
- positive regulation of mitotic cytokinetic process
- positive regulation of neuron migration
- protein localization to microtubule
- regulation of cell cycle
- regulation of establishment of cell polarity
- regulation of mitotic nuclear division
Molecular functions
- ATP binding
- ATP hydrolysis activity
- microtubule binding
- microtubule motor activity
- plus-end-directed microtubule motor activity
- protein homodimerization activity
- WW domain binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of KIF20B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KIF20B as an antibody target. Whether an autoantibody or antibody against KIF20B could matter depends on whether native KIF20B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KIF20B is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label KIF20B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...